EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische Studie

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Louis J Aronne, Deborah Bade Horn, Carel W le Roux, Wayne Ho, Beverly L Falcon, Elisa Gomez Valderas, Sagar Das, Clare J Lee, Leonard C Glass, Cagri Senyucel, Julia P Dunn, SURMOUNT-5 Trial Investigators

New England Journal of Medicine · 03.07.2025 · 393 (1) · 26-36

DOI: 10.1056/nejmoa2416394 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 03.07.2025. Verfasst von Louis J Aronne und 11 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Tirzepatide, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 679-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAdultAgedFemaleHumansMaleMiddle AgedInjections, SubcutaneousMaximum Tolerated DoseWaist CircumferenceWeight LossBody WeightTreatment OutcomeGlucagon-Like Peptide 1Semaglutide

Substanzen

Anti-Obesity AgentsTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York.
  • University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston.
  • Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin.
  • Diabetes Research Centre, Ulster University, Coleraine, United Kingdom.
  • Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles.
  • David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., Dunn, J. P., & SURMOUNT-5 Trial Investigators (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 393(1), 26-36. https://doi.org/10.1056/nejmoa2416394

Vancouver

Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393(1):26-36. doi:10.1056/nejmoa2416394

BibTeX
@article{Aronne2025,
  author = {Aronne, Louis J and Horn, Deborah Bade and le Roux, Carel W and Ho, Wayne and Falcon, Beverly L and Gomez Valderas, Elisa and Das, Sagar and Lee, Clare J and Glass, Leonard C and Senyucel, Cagri and Dunn, Julia P and SURMOUNT-5 Trial Investigators, SURMOUNT-5 Trial Investigators},
  title = {Tirzepatide as Compared with Semaglutide for the Treatment of Obesity},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {1},
  pages = {26--36},
  doi = {10.1056/nejmoa2416394}
}
Kostenlos starten →